Megrez Pharmaceuticals & Chemicals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 22-05-2024
- Paid Up Capital ₹ 0.10 M
as on 22-05-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2020)
- Ebitda
- Net Worth -4.84%
(FY 2020)
- Total Assets 1194.72%
(FY 2020)
About Megrez Pharmaceuticals & Chemicals
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Harsh Baranwal and Tarun Gupta serve as directors at the Company.
- CIN/LLPIN
U74999UP2017PTC096716
- Company No.
096716
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Megrez Pharmaceuticals & Chemicals Private Limited offer?
Megrez Pharmaceuticals & Chemicals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Anti Infective Agent, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Megrez Pharmaceuticals & Chemicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harsh Baranwal  | Director | 06-Sep-2017 | Current |
| Tarun Gupta | Additional Director | 05-Oct-2021 | Current |
Financial Performance of Megrez Pharmaceuticals & Chemicals.
Megrez Pharmaceuticals & Chemicals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth dipped by a decrease of 4.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Megrez Pharmaceuticals & Chemicals?
Unlock access to Megrez Pharmaceuticals & Chemicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Megrez Pharmaceuticals & Chemicals?
Unlock and access historical data on people associated with Megrez Pharmaceuticals & Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Megrez Pharmaceuticals & Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Megrez Pharmaceuticals & Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
